EICHOR
● Active Not Recruiting
Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
Condition: Hematological Malignancies · Sponsor: Janssen Research & Development, LLC
About this study
The purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for Teclistamab and to characterize the safety and tolerability of Teclistamab at the RP2Ds.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (13)
| City of Hope | Duarte, California, United States | — |
| Colorado Blood Cancer Institute | Denver, Colorado, United States | — |
| Icahn School of Medicine at Mount Sinai Program for the Protection of Human Subjects | New York, New York, United States | — |
| Levine Cancer Institute | Charlotte, North Carolina, United States | — |
| University of Pennsylvania | Philadelphia, Pennsylvania, United States | — |
| Hospices Civils de Lyon HCL | Lyon, France | — |
| CHRU Tours Hopital Bretonneau | Tours, France | — |
| VU Medisch Centrum | Amsterdam, Netherlands | — |
| Hosp. Univ. Germans Trias I Pujol | Badalona, Spain | — |
| Hosp Clinic de Barcelona | Barcelona, Spain | — |
| Clinica Univ. de Navarra | Pamplona, Spain | — |
| Hosp Clinico Univ de Salamanca | Salamanca, Spain | — |
+ 1 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03145181